China News Service, Taiyuan, October 18 (Wu Qiong) The reporter learned from the Shanxi Provincial Medical Insurance Bureau on the 18th that from October 20th, all public medical institutions in Shanxi Province will fully implement the national fifth batch of 61 drugs and the “eight provinces and two The selected results of the centralized procurement of 10 drugs in the "Zone" alliance allow patients to enjoy the price reduction effect of drug purchases with volume.
It is understood that the country’s fifth batch of centralized drug procurement has a total of 61 drugs and 251 products selected, with an average price reduction of 56%.
This collection of products covers common diseases such as hypertension, coronary heart disease, diabetes, anti-allergic, anti-infection, gastrointestinal diseases, chronic disease drugs, and drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer. The treatment costs for related patients will be significant. reduce.
Among them, esomeprazole for injection, which is commonly used in clinical treatment of digestive ulcers, decreased by 96.2%, fasudil hydrochloride injection, which improves brain tissue microcirculation, decreased by 95.9%, and gemcitabine hydrochloride for injection, an antitumor drug, decreased by 92.0%. %, the anticoagulant rivaroxaban tablets dropped by 98.3%.
Shanxi participated in Heilongjiang and other "eight provinces and two districts" inter-provincial alliance drug centralized procurement, a total of 10 drugs 12 product specifications were selected, an average decrease of 66.7%.
Among them, the price of bone disease medicine sodium hyaluronate injection dropped from 123.4 yuan to 44.5 yuan, a decrease of 63.9%; the price of antibiotic drug Biapenem dropped from 113 yuan to 30 yuan, a decrease of 73.5%.
While fully implementing the results of price cuts for 71 selected drugs across the province, Shanxi will implement medical insurance fund prepayment, medical insurance payment standards and purchase price coordination, strengthen clinical rational use of drugs, medical insurance fund balance retention incentive assessment, and strengthen the quality supervision of selected drugs And other measures to promote hospitals to give priority to the use of selected drugs with reliable quality and reasonable prices.
After the implementation of these two batches of drugs, the number of national and provincial centralized procurement drugs implemented in Shanxi will reach 277, with an average drop of more than 50%.
The Shanxi Provincial Medical Insurance Bureau stated that in the next step, Shanxi will continue to play an important role in enhancing people’s well-being, promoting the joint reform of the three medical systems, and promoting the healthy development of the pharmaceutical industry. It will take centralized and large-volume procurement of medicines as a coordinated promotion of medical services. An important measure for supply-side reforms, to promote the normalization and institutionalization of centralized drug procurement, to reduce the burden of drug use by the people, and to better ensure that the people have medical treatment.
(over)